Condition: Biliary Tract Cancer
Intervention: Other: Tumour and germline molecular profiling
Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Cancer Research Society
Recruiting
Feeds
10095 items (10095 unread) in 74 feeds
Acinar Cell Carcinoma
(96 unread)
Acinic Cell Carcinoma
(21 unread)
Adenoid Cystic Carcinoma
(223 unread)
Adrenal Gland Cancer
(899 unread)
Ampulla Of Vater
(75 unread)
Anal Cancer
(911 unread)
Angiosarcoma
(174 unread)
Appendix Cancer
(147 unread)
Bile Duct Cancer
(1427 unread)
Brain and CNS
(1389 unread)
Carcinoid
(311 unread)
Endocrine/Neuroendocrine
(968 unread)
Gall Bladder Cancer
(431 unread)
Hemangioendothelioma
(248 unread)
Hepatoblastoma
(123 unread)
Pancreas
(139 unread)
Phyllodes
(95 unread)
PMP and Mucinous Tumors
(62 unread)
Rhabdomyosarcoma
(337 unread)
Sarcoma
(2019 unread)
Trial - Cholangiocarcinoma (46 unread)
-
Molecular Profiling of Advanced Biliary Tract Cancers
Posted: March 24th, 2020, 2:00pm GMT
-
A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
Posted: March 20th, 2020, 2:00pm GMT
Conditions: Colon Cancer; Gastric Cancer; Pancreas Cancer; Rectal Cancer; Cholangiocarcinoma; Small Bowel Cancer; Esophageal Cancer
Intervention: Other: patient engagement platform
Sponsor: Sheba Medical Center
Recruiting -
Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy
Posted: March 16th, 2020, 2:00pm GMT
Conditions: Primary Sclerosing Cholangitis; Cholestasis
Interventions: Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Drug: Placebo of Bezafibrate in addition to standard UDCA therapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting -
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Posted: March 13th, 2020, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Not yet recruiting -
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Posted: March 12th, 2020, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: Pembrolizumab; Drug: Olaparib
Sponsor: Georgetown University
Recruiting -
Chemotherapy FOLFIRINOX in Advanced or Recurrent Cholangiocarcinoma
Posted: March 12th, 2020, 2:00pm GMT
Condition: Cholangiocarcinoma of the Bile Duct
Intervention: Drug: FOLFIRINOX Conventional chemotherapy
Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting -
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
Posted: March 11th, 2020, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: KSP/QRH dimer
Sponsor: Danielle Kim Turgeon
Not yet recruiting -
Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Posted: March 10th, 2020, 2:00pm GMT
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: SNDX-6352
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; AstraZeneca
Not yet recruiting -
Clinical Effect and Safety of PDT and RFA for Unresectable EHCC
Posted: March 10th, 2020, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Procedure: Photodynamic therapy; Procedure: radiofrequency ablation
Sponsor: First People's Hospital of Hangzhou
Recruiting -
Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma
Posted: March 9th, 2020, 2:00pm GMT
Condition: Hepatocellular Carcinoma
Interventions: Drug: Camrelizumab; Combination Product: US/CT-guided Percutaneous Cryoablation
Sponsor: Fudan University
Recruiting -
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Posted: March 6th, 2020, 3:00pm GMT
Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab; Drug: Olaparib
Sponsor: Seoul National University Hospital
Not yet recruiting -
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Posted: March 6th, 2020, 3:00pm GMT
Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab
Sponsor: Seoul National University Hospital
Not yet recruiting -
PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery
Posted: March 4th, 2020, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Apatinib; Drug: PD-1 blocking antibody SHR-1210; Drug: Capecitabine
Sponsor: Shanghai Zhongshan Hospital
Recruiting -
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Posted: February 19th, 2020, 3:00pm GMT
Conditions: Bile Duct Neoplasms; Colorectal Neoplasms
Interventions: Device: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.; Drug: Hepatic artery infusion pump floxuridine and dexamethasone; Drug: Systemic chemotherapy for colorectal liver metastases; Drug: Systemic chemotherapy for intrahepatic cholangiocarcinoma
Sponsor: Michael J Cavnar, MD
Not yet recruiting -
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
Posted: February 11th, 2020, 3:00pm GMT
Conditions: Hepatocellular Carcinoma Stage IIIB; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma; With Hepatocellular Carcinoma; Hepatocellular Carcinoma Stage IV
Intervention: Drug: Colchicine Tablets
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University
Recruiting -
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Posted: February 5th, 2020, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: Pemigatinib
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting -
mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
Posted: February 3rd, 2020, 3:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Liver Cancer; Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: mFOLFIRINOX; Drug: mFOLFIRI; Drug: Floxuridine; Drug: Dexamethasone; Drug: Heparin; Device: Hepatic arterial infusion pump
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Not yet recruiting -
Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Biliary Stricture; Jaundice, Obstructive
Interventions: Device: Biliary brushing with the RX Cytology brush, Boston Scientific; Device: Biliary brushing with the Infinity® brush, US Endoscopy
Sponsor: Société Française d'Endoscopie Digestive
Not yet recruiting -
Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study
Posted: January 27th, 2020, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention:
Sponsor: Beijing Tsinghua Chang Gung Hospital
Recruiting -
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Posted: January 27th, 2020, 3:00pm GMT
Condition: Radiotherapy
Intervention: Radiation: Adaptative MR-Guided Stereotactic Body Radiotherapy
Sponsor: Centre Georges Francois Leclerc
Recruiting -
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Posted: January 23rd, 2020, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: E7090
Sponsor: Eisai Co., Ltd.
Recruiting -
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Posted: January 23rd, 2020, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest; AstraZeneca
Recruiting -
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
Posted: December 26th, 2019, 3:00pm GMT
Condition: Advanced Hepatocellular Carcinoma (HCC)
Interventions: Drug: MGD013 monotherapy; Drug: MGD013 in combination with Brivanib Alaninate
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Not yet recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting -
Futibatinib in Patients With Specific FGFR Aberrations
Posted: December 6th, 2019, 3:00pm GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Not yet recruiting -
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Posted: November 4th, 2019, 3:00pm GMT
Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer
Intervention: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting -
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Posted: September 23rd, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: Fimaporfin and Gemcitabine; Drug: Gemcitabine/Cisplatin chemotherapy
Sponsor: PCI Biotech AS
Recruiting -
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Posted: September 12th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR1 Gene Alteration Positive; FGFR2 Gene Alteration Positive; FGFR3 Gene Alteration Positive; IDH1 Gene Mutation; IDH1 NP_005887.2:p.R132C; IDH1 NP_005887.2:p.R132G; IDH1 NP_005887.2:p.R132H; IDH1 NP_005887.2:p.R132L; IDH1 NP_005887.2:p.R132S; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Drug: Ivosidenib; Drug: Pemigatinib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Not yet recruiting -
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
Posted: September 3rd, 2019, 2:00pm GMT
Conditions: Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: Trifluridine/Tipiracil
Sponsors: Sunnybrook Health Sciences Centre; Taiho Pharma Canada, Inc.
Recruiting -
Participation in Surgical Cancer Care
Posted: August 20th, 2019, 2:00pm GMT
Condition: Cancer
Intervention: Other: Participation with enhanced patient perioperative information
Sponsor: Linkoeping University
Recruiting -
Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Posted: August 16th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting -
The Master Registry of Oncology Outcomes Associated With Testing and Treatment
Posted: July 22nd, 2019, 2:00pm GMT
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Testing: Genome; Diagnostic Test: Testing: Transcriptome; Diagnostic Test: Testing: Proteome; Drug: Treatment: CAR-T
Sponsor: Taproot Health
Not yet recruiting -
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Posted: February 21st, 2019, 3:00pm GMT
Conditions: Melanoma; Cervical Carcinoma; Pancreatic Carcinoma; Triple Negative Breast Cancer; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced or Metastatic Solid Tumors; Prostate Carcinoma; MSI-H; Mismatch Repair Deficiency; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Biological: XmAb®22841; Biological: Pembrolizumab (Keytruda®)
Sponsors: Xencor, Inc.; ICON Clinical Research
Recruiting -
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Posted: January 29th, 2019, 3:00pm GMT
Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Posted: January 14th, 2019, 3:00pm GMT
Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Posted: December 31st, 2018, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Drug: telotristat ethyl
Sponsor: Lexicon Pharmaceuticals
Recruiting -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
Posted: September 4th, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Posted: May 7th, 2018, 2:00pm GMT
Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Colorectal Carcinoma; Non-small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma; Mesothelioma; Neuroendocrine Carcinoma; Cervical Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of the Anus; Castration-Resistant Prostate Carcinoma; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Basal Cell Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Thymoma; Thymic Carcinoma; Squamous Cell Carcinoma of the Penis; Vulvar Carcinoma; Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy; Malignant Adnexal Neoplasms; Non-squamous Cell Salivary Gland Carcinoma
Intervention: Biological: XmAb20717
Sponsors: Xencor, Inc.; ICON plc
Recruiting -
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Posted: July 26th, 2017, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Recruiting -
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Posted: July 2nd, 2017, 2:00pm GMT
Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; Tesaro, Inc.
Recruiting -
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Posted: March 19th, 2015, 2:00pm GMT
Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
Interventions: Drug: Pemigatinib; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab; Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 30th, 2014, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting -
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Posted: May 1st, 2014, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting -
A Study of TAS-120 in Patients With Advanced Solid Tumors
Posted: February 3rd, 2014, 3:00pm GMT
Conditions: Cholangiocarcinoma; Brain Tumor; Urothelial Cancer; Other Tumor Types With FGFR2 Gene Fusions; Activating Mutations; FGFR2 Amplification
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Recruiting